The roles of cyclin-dependent kinase 5 and glycogen synthase kinase 3 in tau hyperphosphorylation

Topic: Disease mechanisms in lab and animal studies

Hyperphosphorylation of the microtubule-associated protein tau is a characteristic feature of neurodegenerative tauopathies including Alzheimer disease. Over-activation of proline-directed kinases, such as cyclin-dependent kinase 5 (Cdk5) and glycogen synthase kinase 3 (GSK3), has been implicated in the aberrant phosphorylation of tau at proline-directed sites. In this study we tested the roles of Cdk5 and GSK3 in tau hyperphosphorylation in vivo using transgenic mice with p25-induced Cdk5 over-activation. We found that over-activation of Cdk5 in young transgenic animals does not induce tau hyperphosphorylation at sites recognized by the antibodies AT8, AT100, PHF-1, and TG3. In fact, we observed that Cdk5 over-activation leads to inhibition of GSK3. However, in old transgenic animals the inhibition of GSK3 is lost and results in increased GSK3 activity, which coincides with tau hyperphosphorylation at the AT8 and PHF-1 sites. Pharmacological inhibition of GSK3 in old transgenic mice by chronic treatment with lithium leads to a reduction of the age-dependent increase in tau hyperphosphorylation. Furthermore, we found that Cdk5, GSK3, and PP2A co-immunoprecipitate, suggesting a functional association of these molecules. Together, these results reveal the role of GSK3 as a key mediator of tau hyperphosphorylation, whereas Cdk5 acts as a modulator of tau hyperphosphorylation via the inhibitory regulation of GSK3. Furthermore, these findings suggest that disruption of regulation of GSK3 activity underlies tau hyperphosphorylation in neurodegenerative tauopathies. Hence, GSK3 may be a prime target for therapeutic intervention in tauopathies including Alzheimer disease.

Key findings

• We found that over-activation of Cdk5 in young transgenic animals does not induce tau hyperphosphorylation at sites recognized by the antibodies AT8, AT100, PHF-1, and TG3.
• In fact, we observed that Cdk5 over-activation leads to inhibition of GSK3.
• However, in old transgenic animals the inhibition of GSK3 is lost and results in increased GSK3 activity, which coincides with tau hyperphosphorylation at the AT8 and PHF-1 sites.
• Furthermore, we found that Cdk5, GSK3, and PP2A co-immunoprecipitate, suggesting a functional association of these molecules.
• Together, these results reveal the role of GSK3 as a key mediator of tau hyperphosphorylation, whereas Cdk5 acts as a modulator of tau hyperphosphorylation via the inhibitory regulation of GSK3.

New to this subject? Start with our plain-English guide: Treatments →

Study details

• Evidence strengthLow

Read the original

• DOI: 10.1074/jbc.m603469200
• PubMed: 16803897
• Original source →

Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.

@article{plattner2006-16803897,
  author  = {Plattner, F. and Angelo, M. and Giese, K. P.},
  title   = {{The roles of cyclin-dependent kinase 5 and glycogen synthase kinase 3 in tau hyperphosphorylation}},
  journal = {The Journal of biological chemistry},
  year    = {2006},
  doi     = {10.1074/jbc.m603469200},
  pmid    = {16803897},
  url     = {https://doi.org/10.1074/jbc.m603469200}
}

Related studies in Drug development

• Subcutaneous administration of liraglutide ameliorates learning and memory impairment by modulating tau hyperphosphorylation via the glycogen synthase kinase-3β pathway in an amyloid β protein induced alzheimer disease mouse model European journal of pharmacology · 2016-04-27 · usefulness score 36/100
• Neuron-specific phosphorylation of Alzheimer's beta-amyloid precursor protein by cyclin-dependent kinase 5 Journal of neurochemistry · 2000-09-01 · usefulness score 36/100
• Glycogen synthase kinase-3beta phosphorylates protein tau and rescues the axonopathy in the central nervous system of human four-repeat tau transgenic mice The Journal of biological chemistry · 2000-12-01 · usefulness score 36/100
• Activation of tau protein kinase I/glycogen synthase kinase-3beta by amyloid beta peptide (25-35) enhances phosphorylation of tau in hippocampal neurons Neuroscience research · 1998-08-01 · usefulness score 36/100
• Glycogen synthase kinase-3 beta phosphorylates tau protein at multiple sites in intact cells Neuroscience letters · 1995-09-01 · usefulness score 36/100
• Spherical aggregates of beta-amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase I/glycogen synthase kinase-3beta Proceedings of the National Academy of Sciences of the United States of America · 2003-05-15 · usefulness score 36/100

Similar studies

• GSK3 and tau: two convergence points in Alzheimer's disease 2013 · Drug development
• Lithium inhibits Alzheimer's disease-like tau protein phosphorylation in neurons 1997 · Drug development
• Lithium reduces tau phosphorylation but not A beta or working memory deficits in a transgenic model with both plaques and tangles 2007 · Drug development
• Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo 2005 · Drug development
• Neuroprotective effects of regulators of the glycogen synthase kinase-3beta signaling pathway in a transgenic model of Alzheimer's disease are associated with reduced amyloid precursor protein phosphorylation 2007 · Drug development
• Induction of hyperphosphorylated tau in primary rat cortical neuron cultures mediated by oxidative stress and glycogen synthase kinase-3 2004 · Drug development

More on Drug development

• A review that covers this ground Glycogen synthase kinase 3: an emerging therapeutic target Trends in molecular medicine · 2002-03-01 · usefulness score 36/100
• Newest in this subject The metabolic-brain axis: GLP-1 signaling, insulin resistance, and obesity pharmacotherapy in neurodegeneration Metabolism: clinical and experimental · 2026-10-30 · Peer-reviewed · usefulness score 45/100
• Newest in this subject Effect of Metformin on tau pathology and proteostasis in cellular and a Drosophila model of Tauopathy Research Square · 2026-10-29 · Preprint — not yet peer-reviewed · usefulness score 16/100

See all studies in Drug development →